Annovis Bio, Inc. (NYSE:ANVS – Get Free Report) was the target of unusually large options trading on Tuesday. Traders bought 3,923 call options on the stock. This represents an increase of 118% compared to the typical volume of 1,803 call options.
Analysts Set New Price Targets
Several analysts have weighed in on ANVS shares. Brookline Capital Management cut Annovis Bio from a “buy” rating to a “hold” rating and set a $9.00 price target on the stock. in a report on Wednesday, February 28th. Canaccord Genuity Group initiated coverage on shares of Annovis Bio in a research note on Friday, December 29th. They issued a “buy” rating and a $36.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Annovis Bio in a research note on Tuesday, April 2nd. Finally, Canaccord Genuity Group initiated coverage on Annovis Bio in a research note on Friday, December 29th. They issued a “buy” rating and a $36.00 target price for the company.
Read Our Latest Stock Report on ANVS
Hedge Funds Weigh In On Annovis Bio
Annovis Bio Price Performance
NYSE ANVS opened at $9.07 on Thursday. Annovis Bio has a 1 year low of $5.42 and a 1 year high of $22.49. The stock has a market capitalization of $99.87 million, a PE ratio of -1.46 and a beta of 1.59. The business’s 50-day moving average is $10.37 and its 200 day moving average is $10.10.
About Annovis Bio
Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.
Featured Articles
- Five stocks we like better than Annovis Bio
- How to Choose Top Rated Stocks
- United Airlines Soars on Earnings Beat
- Manufacturing Stocks Investing
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Stock Sentiment Analysis: How it Works
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.